The treatment of prostate cancer: an overview of current options
- PMID: 11879332
- DOI: 10.1046/j.1523-5394.2001.96009.x
The treatment of prostate cancer: an overview of current options
Abstract
Purpose: The purpose of this report is to discuss the current treatment options available to the patient with prostate cancer in all stages of the disease.
Overview: With the exception of skin cancer, prostate cancer is the most common cancer in men in the United States. Most patients in the current era will present with organ-confined disease, amenable to curative treatment. Treatment for organ-confined disease includes watchful waiting, radical prostatectomy, radiation therapy, and cryosurgery in selective cases. Hormone therapy is the cornerstone of treatment of patients with advanced prostate cancer. There is no curative treatment for hormone-refractory prostate cancer.
Clinical implications: The availability of several therapeutic options for localized prostate cancer warrants careful consideration when planning treatment with curative intent. Patients need to be active participants in decision making, and they must be aware of the benefits and possible complications of the different types of treatment. Patients with advanced prostate cancer need to be aware that hormone treatment will provide temporization and palliation in the majority of cases. Hormone-resistant prostate cancer is refractory to most forms of conventional and experimental therapy.
Similar articles
-
Management of localised prostate cancer: watchful waiting, surgery or radiation therapy, depending on the natural course, which is often relatively slow.Prescrire Int. 2012 Oct;21(131):242-8. Prescrire Int. 2012. PMID: 23185849 Review.
-
[Therapeutic options and controversies in the management of prostate cancer].Rev Prat. 2003 Dec 31;53(20):2263-7. Rev Prat. 2003. PMID: 15018081 French.
-
Management strategies for locally advanced prostate cancer.Drugs Aging. 2006;23(2):119-29. doi: 10.2165/00002512-200623020-00003. Drugs Aging. 2006. PMID: 16536635 Review.
-
Incidence of urethral stricture after primary treatment for prostate cancer: data From CaPSURE.J Urol. 2007 Aug;178(2):529-34; discussion 534. doi: 10.1016/j.juro.2007.03.126. Epub 2007 Jun 13. J Urol. 2007. PMID: 17570425
-
Endocrine treatment of prostate cancer.J Steroid Biochem Mol Biol. 2004 Nov;92(4):287-95. doi: 10.1016/j.jsbmb.2004.10.005. Epub 2004 Dec 31. J Steroid Biochem Mol Biol. 2004. PMID: 15663992 Review.
Cited by
-
The radiosensitization effect of parthenolide in prostate cancer cells is mediated by nuclear factor-kappaB inhibition and enhanced by the presence of PTEN.Mol Cancer Ther. 2007 Sep;6(9):2477-86. doi: 10.1158/1535-7163.MCT-07-0186. Mol Cancer Ther. 2007. PMID: 17876045 Free PMC article.
-
Baculoviruses as Vectors for Gene Therapy against Human Prostate Cancer.J Biomed Biotechnol. 2003;2003(2):79-91. doi: 10.1155/S1110724303209049. J Biomed Biotechnol. 2003. PMID: 12721513 Free PMC article.
-
Novel expressed sequences identified in a model of androgen independent prostate cancer.BMC Genomics. 2007 Jan 26;8:32. doi: 10.1186/1471-2164-8-32. BMC Genomics. 2007. PMID: 17257419 Free PMC article.
-
Arachidonate 12-lipoxygenase may serve as a potential marker and therapeutic target for prostate cancer stem cells.Int J Oncol. 2011 Apr;38(4):1041-6. doi: 10.3892/ijo.2011.901. Epub 2011 Jan 11. Int J Oncol. 2011. PMID: 21225230 Free PMC article.
-
Ligand-specific dynamics of the androgen receptor at its response element in living cells.Mol Cell Biol. 2007 Mar;27(5):1823-43. doi: 10.1128/MCB.01297-06. Epub 2006 Dec 22. Mol Cell Biol. 2007. PMID: 17189428 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical